Third Rock Launches Decibel Therapeutics with $52M Series A
October 16, 2015
Third Rock Ventures has announced the formation of Decibel Therapeutics, a company focused on discovering and developing new medicines to protect, repair and restore hearing. The company is being launched with a $52 million Series A financing led by Third Rock, with participation from SR One. Decibel has already identified one near-term clinical candidate and several other targets for assessment. The company's focus will include pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss as a side effect of treatment, as well as noise-induced, age-related and genetic hearing loss, among other conditions.